Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Join SI Premium – FREE
Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.02, $0.04 worse than the analyst estimate of $0.06. Revenue for the quarter came in at $90.55 million versus the consensus estimate of $92.5 million.
GUIDANCE:
Ironwood Pharma sees FY2025 revenue of $260-290 million, versus the consensus of $287.6 million.
For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Primis Financial (FRST) Misses Q3 EPS by 7c
- Barclays Starts SGHC Limited (SGHC) at Equalweight
- Raymond James Reiterates Market Perform Rating on Byline Bancorp (BY)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
